Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05207722 · ClinicalTrials.gov registry record · Phase 1
CYNK-101 in Combination with Trastuzumab and Pembrolizumab in Patients with Locally Advanced Unresectable or Metastatic HER2-Positive Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma
A Phase 1 study, sponsored by Celularity Incorporated.
- Terminated
- Registry status
- Phase 1
- Development phase
- 1
- Enrollment target
NCT05207722: Clinical Trial Phase 1 study, sponsored by Celularity Incorporated.
NCT05207722 is a Phase 1 study that was terminated before completion, run by Celularity Incorporated. The registered enrollment target is 1 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05207722, a Phase 1 study, was terminated before completion, sponsored by Celularity Incorporated.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 1 participants
- Enrollment target
Study Summary
This study will find the maximum tolerated dose (MTD) of CYNK-101 which contains Natural Killer (NK) cells derived from human placental CD34+ cells and culture-expanded. CYNK-101 will be administered as first-line treatment, following induction therapy consisting of Pembrolizumab, Trastuzumab and a Fluoropyrimidine / Platinum based Chemotherapy regimen. Patients are required to undergo a biopsy for confirmation of HER2 positivity defined as either IHC 3+ or IHC 2+ with a positive fluorescent in-situ hybridization (FISH) or FISH + alone. The safety of this treatment will be evaluated, and researchers will want to learn if NK cells will help in treating patients with Locally Advanced Unresectable or Metastatic HER2-Positive Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma.
Primary Outcome
Phase I
Interventions
- DRUG Pembrolizumab
- DRUG Trastuzumab
- DRUG Cyclophosphamide
- BIOLOGICAL CYNK-101
- DRUG Recombinant Human Interleukin-2
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2022-04-14 |
| Est. Completion | 2024-02-15 |
| Phase | Phase 1 |
Why NCT05207722 stopped before completion
NCT05207722 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 1 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 5 interventions - of which Pembrolizumab is the first listed.
NCT05207722 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05207722 about?
NCT05207722 is a clinical study titled "CYNK-101 in Combination with Trastuzumab and Pembrolizumab in Patients with Locally Advanced Unresectable or Metastatic HER2-Positive Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma". This study will find the maximum tolerated dose (MTD) of CYNK-101 which contains Natural Killer (NK) cells derived from human placental CD34+ cells and culture-expanded. CYNK-101 will be administered as first-line treatment, following induction therapy consisting of Pembrolizumab, Trastuzumab and a ...
What is the current status of trial NCT05207722?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 1 participants. The study started on 2022-04-14. Estimated completion is 2024-02-15.
What interventions are being tested in trial NCT05207722?
The interventions under investigation include: Pembrolizumab (DRUG), Trastuzumab (DRUG), Cyclophosphamide (DRUG), CYNK-101 (BIOLOGICAL), Recombinant Human Interleukin-2 (DRUG).
Who is sponsoring clinical trial NCT05207722?
This trial is sponsored by Celularity Incorporated, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05207722's enrollment target sits among peer trials
1 2001st of 2000 the lowest of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI